Collaboration and Licensing Revenue (Tables)

6 Months Ended

Jun. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenue

The following table summarizes the amounts recorded in the consolidated statements of operations for each significant collaboration and licensing agreement for the three and six months ended June 30, 2015 and 2014.

	Three Months Ended June 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	644	$	4,606	$	5,250
Oragenics, Inc.	307		68		375
Fibrocell Science, Inc.	448		1,470		1,918
Genopaver, LLC	68		867		935
S & I Ophthalmic, LLC	—		890		890
OvaXon, LLC	—		662		662
Intrexon Energy Partners, LLC	625		2,731		3,356
Persea Bio, LLC	125		141		266
Ares Trading S.A.	739		—		739
Other	747		2,043		2,790
Total	$	3,703	$	13,478	$	17,181

	Three Months Ended June 30, 2014
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	644	$	3,697	$	4,341
Oragenics, Inc.	261		52		313
Fibrocell Science, Inc.	448		883		1,331
Genopaver, LLC	68		423		491
S & I Ophthalmic, LLC	—		607		607
OvaXon, LLC	—		579		579
Intrexon Energy Partners, LLC	625		1,210		1,835
Other	471		1,796		2,267
Total	$	2,517	$	9,247	$	11,764

	Six Months Ended June 30, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,288	$	7,763	$	9,051
Oragenics, Inc.	569		76		645
Fibrocell Science, Inc.	896		3,183		4,079
Genopaver, LLC	137		1,467		1,604
S & I Ophthalmic, LLC	—		1,645		1,645
OvaXon, LLC	—		1,306		1,306
Intrexon Energy Partners, LLC	1,250		4,916		6,166
Persea Bio, LLC	250		256		506
Ares Trading S.A.	739		—		739
Other	1,605		4,618		6,223
Total	$	6,734	$	25,230	$	31,964

	Six Months Ended June 30, 2014
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services
ZIOPHARM Oncology, Inc.	$	1,288	$	5,733	$	7,021
Oragenics, Inc.	523		585		1,108
Fibrocell Science, Inc.	896		1,745		2,641
Genopaver, LLC	137		844		981
S & I Ophthalmic, LLC	—		1,486		1,486
OvaXon, LLC	—		748		748
Intrexon Energy Partners, LLC	625		1,210		1,835
Other	930		2,851		3,781
Total	$	4,399	$	15,202	$	19,601

Summary of Deferred Revenue

Deferred revenue consists of the following:

	June 30, 2015		December 31, 2014
Upfront and milestone payments	$	163,094	$	107,228
Prepaid research and development services	11,496		1,045
Prepaid product and service revenues	4,679		4,365
Other	741		571
Total	$	180,010	$	113,209
Current portion of deferred revenue	$	28,737	$	16,522
Long-term portion of deferred revenue	151,273		96,687
Total	$	180,010	$	113,209